3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Classical hematology
16
Plasma cell
2
Thoracic
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
CNS
1
Conditions
Venous Thromboembolism
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thrombosis
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Lung Neoplasms
1
Inflammation
1
Immune System Diseases
1
Colonic Neoplasms
1
Cardiovascular Diseases
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Tinzaparin
1
Rivaroxaban
1
Gemcitabine
1
Aspirin
1
ALT-836
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Venous Thromboembolism
×
Rivaroxaban
×
Genitourinary
×
Clear all
NCT05920343
2025-07-10
PREVENT-GU
Ottawa Hospital Research Institute
Phase 2/3
Recruiting
120 enrolled